Navigation Links
Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog®
Date:3/1/2011

BRIDGEWATER, N.J., March 1, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S. Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.  In December 2010, Valeritas received FDA clearance for the V-Go's use with Eli Lilly's Humalog®.

"With the addition of NovoLog® to the V-Go label, we have demonstrated that the two most widely prescribed fast acting insulins in the United States can be used safely with the V-Go and thereby have increased healthcare professional and patient insulin options available for use with the V-Go Disposable Insulin Delivery Device," said Valeritas CEO Kristine Peterson.  

About the V-Go Disposable Insulin Delivery Device

The V-Go is the first simple, fully disposable device for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.  

The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes. The V-Go is small, lightweight, and worn under the patients' clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.

The V-Go is filled with insulin using a very simple point-of-care filling accessory – the EZ Fill (which will be included with each monthly supply of V-Go devices).  A separate prescription for insulin is required for use with the V-Go.  Humalog® and NovoLog® have both been tested by Valeritas, Inc. and found safe for use with the V-Go Disposable Insulin Delivery Device.

About Valeritas, Inc.

Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.  The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology.  The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing around mealtimes, is the first use of the h-Patch™ technology.

In addition to the V-Go, the Valeritas delivery technology portfolio includes the

h-Patch™ for the delivery of other compounds in addition to insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Delivery System.  These technologies, when combined with certain compounds, are designed to enhance the delivery of a variety of injectable drugs resulting in improved patient acceptance and outcomes.

Headquartered in Bridgewater, NJ, Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, MA. Valeritas' primary investors include MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, ONSET Ventures, ATV Capital, HLM Venture Partners, CHL Medical Partners, Kaiser Permanente Ventures, and Agate Medical Investments.

Information on Valeritas and the V-Go™ Disposable Insulin Delivery Device can be found at www.valeritas.com and www.go-vgo.com.

NovoLog is a registered trademark of Novo Nordisk A/S.

Humalog is a registered trademark of Eli Lilly and Company.


'/>"/>
SOURCE Valeritas, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device
2. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Mylan Receives Approval for Generic Version of Neurontin® Capsules
4. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
5. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
6. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
7. Delcath Systems Receives Refusal to File Letter From FDA
8. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
9. Sevocity, a Division of Conceptual MindWorks, Incs Sevocity Receives ONC-ATCB 2011/2012 Certification
10. Jardogs FollowMyHealth™ Universal Health Record Receives ONC-ATCB Certification
11. AirPal Receives Patent for Inflatable Patient Positioning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... to reach USD 2.06 billion by 2022, according ... Inc. Increasing consumer awareness towards a healthy lifestyle ... next seven years.      (Logo: ... intake coupled with rising health treatment expenditure has ...
(Date:4/26/2016)... April 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Deutsche Bank 41 st Annual Health ... EDT. You are invited to listen to the ... or access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded ... conclusion of the live event and accessible at the links ...
(Date:4/26/2016)... 26, 2016 Research and Markets has ... Risk Analysis of the Biological Medicine Industry in China ... report analyzes the financial assessment and credit risk of ... . The report provides readers with an in-depth understanding ... participants should be aware of. It considers current and ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition Duchenne, a ... and funding for Duchenne research, participated in the April 25 U.S. Food and ... Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in Hyattsville, Maryland ...
(Date:4/29/2016)... ... , ... Pro3rd Grunge is a package of 30 grunge-themed lower thirds created ... characters, and locations without having to set a single keyframe. Choose from a variety ... components. Simply select a preset and drag it into the FCPX timeline. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Orthodontics ... their founders, Dr. Gemmi and Dr. Middleberg, were asked by Invisalign ... nation. During the seminar, titled “Advancing the Biomechanics of Invisalign Clear Aligners,” ...
(Date:4/28/2016)... ... 2016 , ... Sanford Health’s work in cellular therapy and ... and leaders from Sanford Health were selected to participate in the “ Third ... and receive the 2016 Pontifical Key Innovation Award at the Vatican. , The ...
(Date:4/28/2016)... , ... April 28, 2016 , ... Head Over Heels ... 9 Western Championships. The competition will be held at the University of Montana on ... gymnasts west of the Mississippi River. , In order to qualify, Varize needed to ...
Breaking Medicine News(10 mins):